Abstract
The aim of this study was to evaluate whether the incidence of ventricular arrhythmias and heart rate variability were influenced by statin treatment and lipid levels in patients treated with an implantable cardioverter defibrillator (ICD). Heart rate variability measurements were performed in 86 patients with coronary heart disease and an ICD implant. The number of events with ventricular fibrillation and ventricular tachycardia were recorded during a 12-month period. This study lends little support for an antiarrhythmic effect of statins or any relation between plasma lipids and lipoproteins and malignant ventricular arrhythmias in patients with an ICD.
Copyright (c) 2005 S. Karger AG, Basel.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Aged
-
Anti-Arrhythmia Agents / therapeutic use
-
Biomarkers / blood
-
Cholesterol / blood
-
Combined Modality Therapy
-
Coronary Disease / therapy*
-
Defibrillators, Implantable*
-
Female
-
Heart Rate / drug effects*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Incidence
-
Lipids / blood*
-
Male
-
Middle Aged
-
Statistics as Topic
-
Tachycardia, Ventricular / drug therapy
-
Tachycardia, Ventricular / epidemiology
-
Tachycardia, Ventricular / therapy*
-
Treatment Outcome
-
Triglycerides / blood
-
Ventricular Fibrillation / therapy
Substances
-
Adrenergic beta-Antagonists
-
Anti-Arrhythmia Agents
-
Biomarkers
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lipids
-
Triglycerides
-
Cholesterol